



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

6 November 2018

ANNOUNCEMENT



Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SUCCESSFUL REGISTRATION OF FORTACIN™ IN HONG KONG




SUMMARY

This announcement is made by the Company in compliance with the disclosure requirements under Rule 13.09 of the HK Listing Rules and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Directors are pleased to inform the shareholders of the Company and potential investors that on 4 November 2018 the Company was advised by its regulatory agent that it had successfully registered Fortacin™ in Hong Kong with the Hong Kong Drug Office. This registration, together with the import licence already obtained in Macau from the Macau Health Authority, will allow Fortacin™ to be sold, offered for sale and distributed in these regions.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.



This announcement is made by Regent Pacific Group Limited (the “**Company**”) in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Directors of the Company (the “**Board**” or the “**Directors**”) are pleased to inform the shareholders of the Company and potential investors that on 4 November 2018 the Company was advised by its regulatory agent that it had successfully registered Fortacin™ in Hong Kong with the Hong Kong Drug Office. The Hong Kong registration will run for an initial period expiring on 18 October 2023 and thereafter for periods of five (5) years at a time on renewal. This registration, together with the import licence already obtained in Macau from the Macau Health Authority, will allow Fortacin™ to be sold, offered for sale and distributed in these regions.

The Company is in discussions with possible marketing and distribution partners to help facilitate the Macau and Hong Kong roll-out, which is expected in early 2019.

The Company remains in advanced active discussions with a possible strategic commercial partner for the sale of Fortacin™ in China, including in respect of a possible submission by Plethora Solutions Limited, a wholly owned subsidiary of the Company, for a new investigational new drug application to China’s Food and Drug Administration. In addition, the Company remains in discussions for the other remaining key markets of North America, Latin America and the Asia Pacific regions. However, it is not possible to determine with accuracy the timing of completion of any such agreement and no assurance can be given that negotiations will lead to a binding licensing agreement(s) in respect of China or elsewhere or at all.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company (the “Shares”).

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:

James Mellon (*Chairman*)^{*}

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe^{*}

^{*} *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 6 November 2018